Dr. Shore on Immunotherapies for Prostate Cancer

Neal D. Shore, MD
Published: Thursday, Jun 20, 2013

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, gives an overview of the development of immunotherapies for patients with prostate cancer.

Shore believes that the oncology community is getting close to significant breakthroughs in this space. In 2010, sipuleucel-T represented a tremendous breakthrough as the first immunotherapy approved for any metastatic solid tumor. As ipilimumab has been approved for metastatic melanoma, Shore notes that he's excited for data from two phase III trials looking at ipilimumab in advanced prostate cancer.

Unlike sipuleucel-T, ipilimumab is a checkpoint inhibitor, Shore says, and takes the break off of the immune system to let the T cells work in an unchecked way. PROSTVAC is similar to sipuleucel-T in that it is a T cell potentiator, directly stimulating T cells to work more effectively.

Shore says he is excited about preliminary studies exploring better checkpoint inhibitor therapies with fewer side effects and the possibility of combining immunotherapies.

<<< View more from the 2013 ASCO Annual Meeting

SELECTED
LANGUAGE
Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, gives an overview of the development of immunotherapies for patients with prostate cancer.

Shore believes that the oncology community is getting close to significant breakthroughs in this space. In 2010, sipuleucel-T represented a tremendous breakthrough as the first immunotherapy approved for any metastatic solid tumor. As ipilimumab has been approved for metastatic melanoma, Shore notes that he's excited for data from two phase III trials looking at ipilimumab in advanced prostate cancer.

Unlike sipuleucel-T, ipilimumab is a checkpoint inhibitor, Shore says, and takes the break off of the immune system to let the T cells work in an unchecked way. PROSTVAC is similar to sipuleucel-T in that it is a T cell potentiator, directly stimulating T cells to work more effectively.

Shore says he is excited about preliminary studies exploring better checkpoint inhibitor therapies with fewer side effects and the possibility of combining immunotherapies.

<<< View more from the 2013 ASCO Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x